Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.32 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.32 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2299648 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14KIF11P2RY10GPR174 | |
| Hydrochloric Acid SCHEMBL2179314 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14KIF11P2RY10GPR174 | |
| SCHEMBL11962067 | 0.79 | — | — | |
| SCHEMBL12155041 | 0.79 | — | — | |
| SCHEMBL2299653 | 0.79 | — | — | |
| SCHEMBL23127094 | 0.79 | SLC1A1 (0.36) | SMN1; SMN2CA14SLC7A5ANPEPRNPEP | |
| SCHEMBL24648738 | 0.79 | SLC1A1 (0.36) | SMN1; SMN2CA14SLC7A5ANPEPRNPEP | |
| SCHEMBL16382137 | 0.79 | SLC1A1 (0.36) | SMN1; SMN2CA14SLC7A5ANPEPRNPEP | |
| SCHEMBL10799246 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2KIF11CA1CA2 | |
| SCHEMBL10799791 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2KIF11CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | SMN1; SMN2 2240/4885CA14 2375/4885CA12 2507/4885 |
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | SMN1; SMN2 2937/4885CA14 543/4885CA12 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.